US.REGN · Regeneron Pharmaceuticals

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.4782934272892407,
        "turnoverUsdM": 610.48204073836,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.8,
    "stopLevels": {
      "symbol": "US.REGN",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 660.7228,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 3,
        "macd_score": 3,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.7,
      "stop_loss_percent": 5,
      "take_profit_price": 754.5612,
      "target_multiplier": 2.2,
      "technical_strength": 2.35,
      "take_profit_percent": 8.5
    },
    "positionPoints": 1.6,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.714889751633911,
    "stopLossPercent": 4.9565868545784815,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 87.9,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 65.9,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 22
  },
  "market": {
    "ma20": 661.6,
    "ma50": 638.9202,
    "close": 695.18,
    "prevClose": 667.17,
    "avgVolume20": 755418,
    "volumeRatio": 1.16,
    "changePercent": 4.2
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 22,
    "details": {
      "ret_5d": 0.02960646632799646,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 22,
      "vcp_bonus": 2,
      "vol_ratio": 1.1736551595097764,
      "ret_points": 4,
      "vol_points": 2,
      "range_ratio": 1.2154482356081668,
      "volat_points": 2,
      "day_range_pct": 0.029085949381253032,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 8,
      "partial_history": false,
      "pullback_points": 0,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": true,
      "return_window_days": 5,
      "first_breakout_bonus": 2,
      "breakout_quality_points": 2
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 87.9,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 80,
        "contribution": 4
      },
      {
        "raw": 12.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 62,
        "contribution": 12.4
      },
      {
        "raw": 6.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 42.67,
        "contribution": 6.4
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 7.8,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 78,
        "contribution": 7.8
      },
      {
        "raw": 25.3,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 84.33,
        "contribution": 25.3
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 65.9,
    "details": [
      "基本面分析總分: 4/5分",
      "資金流分析總分: 12.4/20分",
      "市場環境分析總分: 6.4/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 7.8/10分",
      "技術信號分析總分: 25.3/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 4,
      "資金流": 12.4,
      "市場環境": 6.4,
      "情緒分析": 4,
      "技術信號": 25.3,
      "風險管理": 7.8
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "良好",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.5,
          "epsPoints": 0,
          "roePoints": 0.4,
          "debtPoints": 0.5,
          "marginPoints": 0.75,
          "turnoverUsdM": 610.48204073836,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 2.4,
          "obvPoints": 3.2,
          "vwapPoints": 3.2,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.REGN",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 1.8,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 18.67
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 708.0634979000001,
                "ma50": 716.7494019999999,
                "name": "QQQ",
                "close": 675.48999,
                "points": 0.4
              },
              "spy": {
                "ma20": 746.6510067000002,
                "ma50": 744.8574021799999,
                "name": "SPY",
                "close": 740.85999,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.4782934272892407,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 1.8,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 1,
              "positiveHits": 4,
              "sentimentScoreRaw": 0.9
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141043763,
                "url": "https://finnhub.io/api/news?id=6c84d7d750b41c6ec5b633e7fd9566616bea044729a9361813a17c1395213ed1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron's Q2 results could hinge on Dupixent profits and strong Eylea HD, Libtayo sales as investors watch earnings, buybacks and pipeline updates.",
                "category": "company",
                "datetime": 1785246060,
                "headline": "Will REGN's Q2 Earnings Get a Boost From Dupixent and Eylea HD?"
              },
              {
                "id": 141034123,
                "url": "https://finnhub.io/api/news?id=adf7566752707809ac1d4a4165de8ef98d81bfea02088471ae74376115909895",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Beyond analysts' top-and-bottom-line estimates for Regeneron (REGN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.",
                "category": "company",
                "datetime": 1785158116,
                "headline": "Curious about Regeneron (REGN) Q2 Performance? Explore Wall Street Estimates for Key Metrics"
              },
              {
                "id": 141004022,
                "url": "https://finnhub.io/api/news?id=c4e3b057fbbd003f030babd2032fbc4e4623a656806e65fb2014c88536dd883b",
                "image": "https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp",
                "source": "ChartMill",
                "related": "REGN",
                "summary": "Regeneron (REGN) offers value investors a unique opportunity with a P/E of 14.29, strong profitability, and solid financial health. The stock combines a discount valuation with decent growth prospects, making it a compelling value trap avoidant pick.",
                "category": "company",
                "datetime": 1784889031,
                "headline": "Regeneron Pharmaceuticals (NASDAQ:REGN): A Quality Value Stock with Decent Growth and a Clear Discount"
              },
              {
                "id": 140994890,
                "url": "https://finnhub.io/api/news?id=a11487ca36d59f76d73368afe4b57063b7977d61e9ce19298653a8eabe56357d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1784815230,
                "headline": "Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release"
              },
              {
                "id": 140933149,
                "url": "https://finnhub.io/api/news?id=8ae68d4a800fc5471e38e88c051052ae12119c3adac3b0bb978c2424b300b331",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Recent Performance Snapshot For Regeneron Pharmaceuticals Regeneron Pharmaceuticals (REGN) has drawn investor attention after a recent stretch of mixed share performance, with the stock up over the past month but lower over the past 3 months and year to date. The company, valued at about US$67.6b with last close near US$678.94, also reports annual revenue of US$14.9b and net income of US$4.4b from its portfolio of medicines across eye, inflammatory, cardiovascular, neurological, infectious...",
                "category": "company",
                "datetime": 1784297454,
                "headline": "Regeneron Pharmaceuticals (REGN) Rebounds As Undervalued View Holds, Is The Upside Already Priced In?"
              },
              {
                "id": 140887085,
                "url": "https://finnhub.io/api/news?id=e80265d43e9bf4cf595492c9e8e45c692cd5e991d6279735fca90263da6930e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Longleaf Partners, managed by Southeastern Asset Management, released its second-quarter 2026 investor letter for its “Partners Fund”. A copy of the letter can be downloaded here. The letter states that the portfolio holdings are attractive now based on both P/V and P/FCF metrics. However, the Fund returned 3.87% in the quarter, significantly lagging the S&P 500’s […]",
                "category": "company",
                "datetime": 1783953215,
                "headline": "Disappointing Trial Results Hurt Regeneron Pharmaceuticals (REGN) in Q2"
              },
              {
                "id": 140841926,
                "url": "https://finnhub.io/api/news?id=89e82e012b0d443a31bfd3685cb33dbaf54cd056dfc54108967a6403c1edfcf9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best healthcare stocks on our list. TheFly reported on July 6 that HSBC reduced its price target on REGN to $800 from $990 while maintaining a Buy rating on the shares. The adjustment […]",
                "category": "company",
                "datetime": 1783522206,
                "headline": "Is Regeneron Pharmaceuticals, Inc. (REGN) Stock Still a Biotech Leader After Analyst Price Target Cut?"
              },
              {
                "id": 140833172,
                "url": "https://finnhub.io/api/news?id=4d6a02d25598162ebba28013e4ff0e61ec8802cd929030da0ee28acfb4126c8b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1783440605,
                "headline": "Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?"
              }
            ],
            "raw_source": [
              {
                "id": 141045042,
                "url": "https://finnhub.io/api/news?id=74a07e92f5bf8973c5629f05b56d1f5b6fde7b9ac8cafada7146e4a1587ad2e5",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2287291267/image_2287291267.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "Outlook Therapeutics, Inc. wins FDA & EU approval for LYTENAVA for wet AMD, but cash burn and competition loom. Click for this OTLK update.",
                "category": "company",
                "datetime": 1785246276,
                "headline": "Outlook: 'Hold' - Caution On LYTENAVA FDA Approval And Cash Needs"
              },
              {
                "id": 141043763,
                "url": "https://finnhub.io/api/news?id=6c84d7d750b41c6ec5b633e7fd9566616bea044729a9361813a17c1395213ed1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron's Q2 results could hinge on Dupixent profits and strong Eylea HD, Libtayo sales as investors watch earnings, buybacks and pipeline updates.",
                "category": "company",
                "datetime": 1785246060,
                "headline": "Will REGN's Q2 Earnings Get a Boost From Dupixent and Eylea HD?"
              },
              {
                "id": 141037294,
                "url": "https://finnhub.io/api/news?id=99938822465e7b5de20bc365ef0d223371b586ebe8823ea0152df5f38df61316",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.",
                "category": "company",
                "datetime": 1785188942,
                "headline": "3 Cash-Heavy Stocks with Questionable Fundamentals"
              },
              {
                "id": 141034121,
                "url": "https://finnhub.io/api/news?id=04c27fd8bb67bc94baa328a4ab1aaa96c7a311d0bad8696a3c72ef48d6dc9fb5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "The current standard of care for food allergy focuses on strict avoidance of the offending allergen and the prompt use of an adrenaline auto-injector (AAI) in the event of an allergic reaction. While antihistamines, corticosteroids, and bronchodilators are frequently used to manage associated symptoms, these agents do not treat anaphylaxis and should only be considered adjunctive therapies alongside epinephrine.",
                "category": "company",
                "datetime": 1785162660,
                "headline": "Food Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsight"
              },
              {
                "id": 141034122,
                "url": "https://finnhub.io/api/news?id=8e9aa6bbb3bd47006e8d352e5b42d80856d7f3dda3c468294143158d64554639",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1785160813,
                "headline": "Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth"
              },
              {
                "id": 141034123,
                "url": "https://finnhub.io/api/news?id=adf7566752707809ac1d4a4165de8ef98d81bfea02088471ae74376115909895",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Beyond analysts' top-and-bottom-line estimates for Regeneron (REGN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.",
                "category": "company",
                "datetime": 1785158116,
                "headline": "Curious about Regeneron (REGN) Q2 Performance? Explore Wall Street Estimates for Key Metrics"
              },
              {
                "id": 141032185,
                "url": "https://finnhub.io/api/news?id=1d131c897db42ea543d59bae1c01b213e7d1915e0bbb0ee5d34da31eeea3e96a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Most biotech investors treat FBT and IBB as two names for the same trade, but the structural differences buried in their index methodologies have produced shockingly different outcomes depending on where the market's momentum actually lives.",
                "category": "company",
                "datetime": 1785151515,
                "headline": "FBT and IBB Are Not the Same Biotech Bet, and 5 Years of Returns Prove It"
              },
              {
                "id": 141012380,
                "url": "https://finnhub.io/api/news?id=1049f08222cb659a27f732cbe315d0815331fce9aae8adcb12d874d1f0f61c7c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2262233592/image_2262233592.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals, Inc. buy case: Dupixent & Libtayo fuel growth despite volatility & Eylea biosimilar risks; margins to recover. Click for an REGN update.",
                "category": "company",
                "datetime": 1784924522,
                "headline": "Regeneron: I'm Not Concerned About The Declining ROIC And Operating Margins"
              },
              {
                "id": 141010195,
                "url": "https://finnhub.io/api/news?id=fa1c7e9783c0e22bfa16308899c315d1134689a5ddff80c6947cf4725f43b382",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2244450943/image_2244450943.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "Regeneron (REGN) is a Buy ahead of Q2 2026 earnings: Dupixent, Eylea HD, and Libtayo growth plus pipeline catalysts and $3B buyback. Read the latest analysis on the stock here.",
                "category": "company",
                "datetime": 1784913318,
                "headline": "Regeneron Q2 Earnings Preview: Not Expecting Miracles - At Least In The Short Term"
              },
              {
                "id": 141009943,
                "url": "https://finnhub.io/api/news?id=ccfe3bcf2870e38ecadf1a28f164baa124e92229084671966bcacc0ee503a9f4",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/24/Gentilly--France--March-21--2021-Sign-An.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Sanofi discontinued amlitelimab for atopic dermatitis after reviewing phase 3 efficacy and safety data, ending plans for regulatory filings.",
                "category": "company",
                "datetime": 1784902230,
                "headline": "Sanofi Drops Dupixent Successor Candidate After Assessing Data"
              },
              {
                "id": 141004022,
                "url": "https://finnhub.io/api/news?id=c4e3b057fbbd003f030babd2032fbc4e4623a656806e65fb2014c88536dd883b",
                "image": "https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp",
                "source": "ChartMill",
                "related": "REGN",
                "summary": "Regeneron (REGN) offers value investors a unique opportunity with a P/E of 14.29, strong profitability, and solid financial health. The stock combines a discount valuation with decent growth prospects, making it a compelling value trap avoidant pick.",
                "category": "company",
                "datetime": 1784889031,
                "headline": "Regeneron Pharmaceuticals (NASDAQ:REGN): A Quality Value Stock with Decent Growth and a Clear Discount"
              },
              {
                "id": 140994890,
                "url": "https://finnhub.io/api/news?id=a11487ca36d59f76d73368afe4b57063b7977d61e9ce19298653a8eabe56357d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1784815230,
                "headline": "Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release"
              },
              {
                "id": 140997893,
                "url": "https://finnhub.io/api/news?id=b05cf4ad0bd4513db5ec391f3a7c6ed213441e8c288da8a763415c2a2f7643cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals is set to report its second-quarter results this month, with analysts expecting a double-digit decline in earnings year over year.",
                "category": "company",
                "datetime": 1784807248,
                "headline": "Here's What to Expect From Regeneron Pharmaceuticals’ Next Earnings Report"
              },
              {
                "id": 140973836,
                "url": "https://finnhub.io/api/news?id=e98bbcd3c40e9eb1c069bf812abf8cb1de619dd38fa0d0df460fe4f786bb9509",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1784640912,
                "headline": "10 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 140971317,
                "url": "https://finnhub.io/api/news?id=c278d97bc59d8196ff93308826986096ccbe0d1319dfd3a5d7b3e592e65d20bc",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Guggenheim  analyst Brad Canino   maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $995 to $1000.",
                "category": "company",
                "datetime": 1784627476,
                "headline": "Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1000"
              },
              {
                "id": 140966295,
                "url": "https://finnhub.io/api/news?id=d440e730e24cb5ce5eb60afe174f58480c966c840920b3fc5662af046988a779",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026). Q2 2026 Highlights1 Group revenue of US$247 million, up 7% quarter-over-quarter (QoQ) and up 21% year-over-year (YoY). Precision Medicine continues to deliver strong growth, revenue of US$202 million, up 9% QoQ and up 30% YoY. Telix expects FY 20",
                "category": "company",
                "datetime": 1784590260,
                "headline": "Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress"
              },
              {
                "id": 140965383,
                "url": "https://finnhub.io/api/news?id=252d2af92d35c827be0d28207193e18bcbf3b37d6beb9fe055e4471376919788",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/20/Merck.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "For the tens of millions of Americans who cannot push their LDL cholesterol (trivially known as "bad cholesterol") low enough on statins alone, the strongest backup has meant needles. That changed on July 16,",
                "category": "company",
                "datetime": 1784567501,
                "headline": "Merck Just Won The Race For The First Cholesterol Pill: What It Means For Your Heart And Your Portfolio"
              },
              {
                "id": 140962520,
                "url": "https://finnhub.io/api/news?id=3fcd8a7f90109f3e48ee2af910cd36f315790c604398fe6a3efe26ab9898034f",
                "image": "",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "",
                "category": "company",
                "datetime": 1784556973,
                "headline": "4D Molecular: 'Buy' Wet-AMD Study Readouts 2027 And DME Expansion Opportunity"
              },
              {
                "id": 140958785,
                "url": "https://finnhub.io/api/news?id=d28bdf368ec5f89da56b8e174ca223fba85b3a87c9fd70da8d48704256066a10",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Biohaven Ltd. (NYSE: BHVN) (\"Biohaven\"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced that new data on BHV-1530, its FGFR3-directed antibody-drug conjugate (ADC) using a novel topoisomerase I (TopoIx) payload, will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, to be held October 23-27 in Madrid, Spain.",
                "category": "company",
                "datetime": 1784547000,
                "headline": "Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload"
              },
              {
                "id": 140933149,
                "url": "https://finnhub.io/api/news?id=8ae68d4a800fc5471e38e88c051052ae12119c3adac3b0bb978c2424b300b331",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Recent Performance Snapshot For Regeneron Pharmaceuticals Regeneron Pharmaceuticals (REGN) has drawn investor attention after a recent stretch of mixed share performance, with the stock up over the past month but lower over the past 3 months and year to date. The company, valued at about US$67.6b with last close near US$678.94, also reports annual revenue of US$14.9b and net income of US$4.4b from its portfolio of medicines across eye, inflammatory, cardiovascular, neurological, infectious...",
                "category": "company",
                "datetime": 1784297454,
                "headline": "Regeneron Pharmaceuticals (REGN) Rebounds As Undervalued View Holds, Is The Upside Already Priced In?"
              },
              {
                "id": 140930770,
                "url": "https://finnhub.io/api/news?id=a9cb5ef50d046f2090172e80e8d04609cceed9932ff390ad50fd6714924f060a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "The weight-loss boom has created one of the market's biggest opportunities — and some of its most punishing failures.",
                "category": "company",
                "datetime": 1784284758,
                "headline": "The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea"
              },
              {
                "id": 140921023,
                "url": "https://finnhub.io/api/news?id=c841521090eb2d0487f8096cf5c42fe77514039d13a26ba38fdbc226aa19cbce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Merck snagged the first-ever approval for a PCSK9 pill to lower LDL cholesterol, starting a new rivalry with injection-makers.",
                "category": "company",
                "datetime": 1784216357,
                "headline": "Merck Snags A First-Of-Its-Kind Approval, And Shares Jump"
              },
              {
                "id": 140919808,
                "url": "https://finnhub.io/api/news?id=9f49b8a6e7640a41f99b1c8bfc28e099d45c10878a320d2650880060055de93e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Merck snagged the first-ever approval for a PCSK9 pill to lower LDL cholesterol, starting a new rivalry with injection-makers.",
                "category": "company",
                "datetime": 1784207534,
                "headline": "Dow Jones' Merck Snags A First-Of-Its-Kind Approval, And Jumps"
              },
              {
                "id": 140919919,
                "url": "https://finnhub.io/api/news?id=ac38e40815783f8ec5171d72b4c86aa0d5496672e10888f4bb0f5347b866864d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.",
                "category": "company",
                "datetime": 1784207177,
                "headline": "Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside"
              },
              {
                "id": 140919811,
                "url": "https://finnhub.io/api/news?id=12d3e8fb22281e211a912d0e9096c6e537c6d8e683867a1bce697f16ecc10d27",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "It’s the first pill that lowers blood cholesterol far better than statins—medicines that a quarter of adults take to reduce their risk of heart attack and stroke.",
                "category": "company",
                "datetime": 1784204220,
                "headline": "Merck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pill"
              },
              {
                "id": 140918861,
                "url": "https://finnhub.io/api/news?id=7877303fb718b2579c613cce560673cb9c26ae710beefbc833cb3e4474640c02",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "It’s the first pill that lowers blood cholesterol far better than statins—medicines that a quarter of adults take to reduce their risk of heart attack and stroke.",
                "category": "company",
                "datetime": 1784198700,
                "headline": "Merck Gets Approval for Powerful Cholesterol-Cutting Pill"
              },
              {
                "id": 140907181,
                "url": "https://finnhub.io/api/news?id=59f972a7a9f026056ea067c0867e1c956703b0f6ef65b52eed5506da5d5aab38",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2260474979/image_2260474979.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "Global food delivery platform Delivery Hero was a contributor for the quarter. French pay-TV operator Canal+ contributed positively in the quarter.",
                "category": "company",
                "datetime": 1784099340,
                "headline": "Longleaf Partners Global Fund Q2 2026 Portfolio Review"
              },
              {
                "id": 140895350,
                "url": "https://finnhub.io/api/news?id=56392c5613eca56c189c98c23461b49b1ee98906f44c4285a191c6e347349fc5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.",
                "category": "company",
                "datetime": 1784018351,
                "headline": "1 Large-Cap Stock with Exciting Potential and 2 We Turn Down"
              },
              {
                "id": 140888428,
                "url": "https://finnhub.io/api/news?id=ed15eb87356bea39d17c294679a13f32dbb5cc7c416f7aa1579ca7722654403b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.",
                "category": "company",
                "datetime": 1783964231,
                "headline": "Own Regeneron For Biotech Growth? Incyte Is Making Its Case."
              },
              {
                "id": 140889660,
                "url": "https://finnhub.io/api/news?id=988faa5279f6bb7023f37e0c82bdbb474e0802b57d4e2da7d56058e5bd5f2aa0",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2221411629/image_2221411629.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "The Baird Chautauqua Global Growth Fund Net Investor Class returned +12.18% during the quarter, underperforming the MSCI ACWI Index® ND, which returned +14.93%.",
                "category": "company",
                "datetime": 1783956780,
                "headline": "Baird International And Global Growth Funds Q2 2026 Contributors And Detractors"
              },
              {
                "id": 140887085,
                "url": "https://finnhub.io/api/news?id=e80265d43e9bf4cf595492c9e8e45c692cd5e991d6279735fca90263da6930e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Longleaf Partners, managed by Southeastern Asset Management, released its second-quarter 2026 investor letter for its “Partners Fund”. A copy of the letter can be downloaded here. The letter states that the portfolio holdings are attractive now based on both P/V and P/FCF metrics. However, the Fund returned 3.87% in the quarter, significantly lagging the S&P 500’s […]",
                "category": "company",
                "datetime": 1783953215,
                "headline": "Disappointing Trial Results Hurt Regeneron Pharmaceuticals (REGN) in Q2"
              },
              {
                "id": 140855484,
                "url": "https://finnhub.io/api/news?id=c0cd0801b5c02048a5b44105a521a010dded32916b1e208738925af61171d70d",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Piper Sandler  analyst Biren Amin   maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and lowers the price target from $855 to $854.",
                "category": "company",
                "datetime": 1783596935,
                "headline": "Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $854"
              },
              {
                "id": 140850358,
                "url": "https://finnhub.io/api/news?id=840cbddb211ad3a61dbdba03223eb2cf874f8da5b0b48f025699b494ac5f7406",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2256411028/image_2256411028.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "Novo Nordisk regains competitive ground in obesity with the strong launch of the Wegovy pill, reversing some of the recent underperformance against Eli Lilly.",
                "category": "company",
                "datetime": 1783586769,
                "headline": "Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry"
              },
              {
                "id": 140841649,
                "url": "https://finnhub.io/api/news?id=46cf1067762772bdaff0bf3cd43eb85b6816d116b9c6119f06b2aaa77d698dba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th",
                "category": "company",
                "datetime": 1783523510,
                "headline": "Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says"
              },
              {
                "id": 140841926,
                "url": "https://finnhub.io/api/news?id=89e82e012b0d443a31bfd3685cb33dbaf54cd056dfc54108967a6403c1edfcf9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best healthcare stocks on our list. TheFly reported on July 6 that HSBC reduced its price target on REGN to $800 from $990 while maintaining a Buy rating on the shares. The adjustment […]",
                "category": "company",
                "datetime": 1783522206,
                "headline": "Is Regeneron Pharmaceuticals, Inc. (REGN) Stock Still a Biotech Leader After Analyst Price Target Cut?"
              },
              {
                "id": 140855485,
                "url": "https://finnhub.io/api/news?id=d6f206bfef7e017adac77aab5eb749c790f92eaf3345efcdd764524415f17e5a",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Morgan Stanley  analyst Matthew Harrison   maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and lowers the price target from $788 to $730.",
                "category": "company",
                "datetime": 1783516434,
                "headline": "Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Lowers Price Target to $730"
              },
              {
                "id": 140840573,
                "url": "https://finnhub.io/api/news?id=5e139a297017ff79fead3a17df77dd2984859059085fd34751ce71e2a30a986a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.",
                "category": "company",
                "datetime": 1783514909,
                "headline": "Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside"
              },
              {
                "id": 140832952,
                "url": "https://finnhub.io/api/news?id=a07c9c4cef97cce487e30f32d0b1056e59bd7c136669ff319a0aef87895b94ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking. “There is a move in biotech that we have not ... Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”",
                "category": "company",
                "datetime": 1783441817,
                "headline": "Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”"
              },
              {
                "id": 140833172,
                "url": "https://finnhub.io/api/news?id=4d6a02d25598162ebba28013e4ff0e61ec8802cd929030da0ee28acfb4126c8b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1783440605,
                "headline": "Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?"
              },
              {
                "id": 140841043,
                "url": "https://finnhub.io/api/news?id=12c02f3b42d6acfc4e88828c4b42679f9a7044b0798822902f1d93530c31528e",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and lowers the price target from $707 to $696.",
                "category": "company",
                "datetime": 1783424730,
                "headline": "RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Lowers Price Target to $696"
              },
              {
                "id": 140830635,
                "url": "https://finnhub.io/api/news?id=75ff55444d27e8f3d89d3170bf842d761a354018cf7e1d98b438f1439b97a3c2",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Truist Securities  analyst Gregory Renza   maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and lowers the price target from $778 to $769.",
                "category": "company",
                "datetime": 1783409760,
                "headline": "Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $769"
              },
              {
                "id": 140830636,
                "url": "https://finnhub.io/api/news?id=beaa32b381630ac9c7fa765930fa1a0aeee38b56e401674acb1d5a6947427763",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/07/Meta-Faces-Child-Safety-Case.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Top Wall Street analysts upgraded FSLR, META, WM, NET, and REGN stocks. Check out analyst ratings page for more details and opinions.",
                "category": "company",
                "datetime": 1783407965,
                "headline": "This Meta Platforms Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday"
              },
              {
                "id": 140830637,
                "url": "https://finnhub.io/api/news?id=f75687cc613ee906e5e0954e05c95195b553761ea6e8d86f1fff6704b6d0ce57",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Benchmark  analyst Robert Wasserman   upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Hold to Buy and announces $185 price target.",
                "category": "company",
                "datetime": 1783406269,
                "headline": "Benchmark Upgrades Regeneron Pharmaceuticals to Buy, Announces $185 Price Target"
              },
              {
                "id": 140822583,
                "url": "https://finnhub.io/api/news?id=a1cfc708dc4e87791be5070950f211a0e8b9d48ad9ed86bfaee9b1c7d09f3ad9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "ALNY's advancing pipeline and partnered programs can expand future revenue sources alongside its growing portfolio of approved therapies.",
                "category": "company",
                "datetime": 1783353300,
                "headline": "Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?"
              },
              {
                "id": 140824869,
                "url": "https://finnhub.io/api/news?id=3d83616382044bd70fdef51a59d54cc487cf4605dc293cb8b8cc0b8d6ade8006",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "HSBC  analyst Rajesh Kumar   maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and lowers the price target from $990 to $880.",
                "category": "company",
                "datetime": 1783349660,
                "headline": "HSBC Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $880"
              },
              {
                "id": 140824870,
                "url": "https://finnhub.io/api/news?id=a1e0747d0ad92b579fb51885e239a74404901f8d584a3a322b4bdda34671cb5d",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and lowers the price target from $785 to $750.",
                "category": "company",
                "datetime": 1783327963,
                "headline": "Cantor Fitzgerald Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $750"
              },
              {
                "id": 140808515,
                "url": "https://finnhub.io/api/news?id=d1439d6538b406ae76f633132ce34eae8ae8ca70f2fdb880ca15319187665c9b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA acceptance with Priority Review for cemdisiran in generalized myasthenia gravis. The EMA has also accepted the marketing application for cemdisiran, aligning regulatory review on both sides of the Atlantic. Phase 3 trial data for cemdisiran were published in The Lancet, providing peer reviewed clinical evidence for the therapy. Regeneron Pharmaceuticals comes into this news with its stock at $654.27 and a mixed recent track record,...",
                "category": "company",
                "datetime": 1783181730,
                "headline": "Regeneron (REGN) Secures FDA Priority Review And EMA Acceptance For Cemdisiran"
              },
              {
                "id": 140807790,
                "url": "https://finnhub.io/api/news?id=4f042327ea101f7ede42241981efccaed41c4b3fff4827a34c619f40a41952f0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Regeneron Pharmaceuticals stock has gained 20.2% over the past year, yet its current valuation checks still lean toward the shares looking inexpensive rather than stretched. Over the last 12 months, Regeneron Pharmaceuticals has returned 20.2%, which puts recent investors in profit while raising the question of how much value is left on the table. Regulatory momentum around treatments such as cemdisiran and progress in areas like weight loss can support growth expectations. The risk is that...",
                "category": "company",
                "datetime": 1783177734,
                "headline": "Regeneron (REGN) Stock Looks Undervalued Even After A 20% Gain"
              },
              {
                "id": 140798404,
                "url": "https://finnhub.io/api/news?id=89283f6b12cb8740b756d9639dc2969aaa42d6e574a4170827f3d8a5cfbfe8e6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Dupilumab's growth is driven by its established market presence, new indications like COPD, broad multi-indication use, and strong clinical performance. Recent approvals and phase III trial successes, coupled with its diverse application across conditions, create substantial market opportunities and competitive advantages.Dublin, July 03, 2026 (GLOBE NEWSWIRE) -- The \"Dupilumab Sales Forecast, and Market Size Analysis - 2034\" has been added to ResearchAndMarkets.com's offering. Key Factors Drivi",
                "category": "company",
                "datetime": 1783068000,
                "headline": "Dupilumab Achieves Record $11.9 Billion in Global Sales Amidst Continued Growth"
              },
              {
                "id": 140773506,
                "url": "https://finnhub.io/api/news?id=3ab4dfd96abdfe37327fb0d9480fd0a8290b9f1d3cbfe26e38b29b5d96d5f202",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "ABBV surged nearly 11% in a week as acquisitions, new approvals and pipeline expansion strengthen confidence in its long-term growth strategy.",
                "category": "company",
                "datetime": 1782837240,
                "headline": "What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?"
              },
              {
                "id": 140772789,
                "url": "https://finnhub.io/api/news?id=de3f318bb1515c1dee051c15eb7470cc6fbc1f3e800340946c3b41a4d183288d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "Seven pharma companies have been selected for the FDA PreCheck pilot – a framework intended to bolster the US drug supply chain.",
                "category": "company",
                "datetime": 1782833505,
                "headline": "Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme"
              },
              {
                "id": 140771572,
                "url": "https://finnhub.io/api/news?id=b935258c1075a4fd16e03ae08e3de8772954d64711d60721af0c987486266f27",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "The FDA estimates the PreCheck program could save participating companies up to 14 months by reviewing facilities while they are still under construction",
                "category": "company",
                "datetime": 1782817844,
                "headline": "FDA PreCheck pilot program selects Eli Lilly, Regeneron"
              },
              {
                "id": 140771649,
                "url": "https://finnhub.io/api/news?id=df934937b261c9466a7c6c108019d160deae68a8e1fc6b22ec8410573e9f18a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "REGN",
                "summary": "The newly formed biotech will use the funds to take its eczema bispecific, TALA-125, through to Phase IIb proof-of-concept trials.",
                "category": "company",
                "datetime": 1782816796,
                "headline": "Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger"
              },
              {
                "id": 140772580,
                "url": "https://finnhub.io/api/news?id=a1dbaf2707146a9b63d62e4d0242f6919ac899d858291284c9391b392a71123b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/30/Motala--Sweden--7-January-2023-Fda-Logo-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "FDA names seven companies to its PreCheck pilot to speed U.S. drug manufacturing reviews after receiving more than 80 applications.",
                "category": "company",
                "datetime": 1782814640,
                "headline": "Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness"
              },
              {
                "id": 140781617,
                "url": "https://finnhub.io/api/news?id=595578358436c02ca69098e100d543c131ea3f3936c4b8b6d4cea2efc2233f2e",
                "image": "https://image.cnbcfm.com/api/v1/image/108326901-1782402782515-gettyimages-2282733148-AFP_B8BN4GJ.jpeg?v=1782405357&w=1920&h=1080",
                "source": "CNBC",
                "related": "REGN",
                "summary": "Here are five key things investors need to know to start the trading day.",
                "category": "company",
                "datetime": 1782805099,
                "headline": "SCOTUS decisions, Dow at 52,000, the retirement savings gap and more in Morning Squawk"
              },
              {
                "id": 140766217,
                "url": "https://finnhub.io/api/news?id=488e3e2c93c13800334fb14b1876f80a9a8aa7c1ac7f6c72ca089bd9f5f3ff34",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2241146296/image_2241146296.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "REGN",
                "summary": "Big pharma’s patent cliff may be overstated: layered IP, incremental innovation, and smart licensing extend exclusivity and growth. Click here to read more.",
                "category": "company",
                "datetime": 1782752400,
                "headline": "Big Pharma's Looming Patent Cliff Period And How It Is Trying To Address It"
              },
              {
                "id": 140767078,
                "url": "https://finnhub.io/api/news?id=16a890f2d949d02699e5446ef6360f37c8e0299f410432efe38abbe7227fd3f1",
                "image": "",
                "source": "Benzinga",
                "related": "REGN",
                "summary": "https://www.cnbc.com/2026/06/29/eli-lilly-regeneron-in-fda-precheck-manufacturing-program.html?&qsearchterm=eli%20lilly",
                "category": "company",
                "datetime": 1782744903,
                "headline": "'Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities' - CNBC"
              },
              {
                "id": 140781620,
                "url": "https://finnhub.io/api/news?id=b6f68c2f88eb4507260ba26dbf69e3ee5ebe1e97e15071c48a33ba6ef608e712",
                "image": "https://image.cnbcfm.com/api/v1/image/108203002-17586586832025-09-23t201602z_1200746466_rc2oxgauogov_rtrmadp_0_usa-lilly.jpeg?v=1782769813&w=1920&h=1080",
                "source": "CNBC",
                "related": "REGN",
                "summary": "Eli Lilly and Regeneron are among the first seven companies the FDA has selected for its PreCheck Pilot Program, CNBC has learned.",
                "category": "company",
                "datetime": 1782744603,
                "headline": "Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities"
              },
              {
                "id": 140760509,
                "url": "https://finnhub.io/api/news?id=337ac098885636449238758e63c48f4fad5c91798a779231f37aa746dc0a730c",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_39_9880df21cf.webp",
                "source": "ChartMill",
                "related": "REGN",
                "summary": "The week closed with the Strait of Hormuz still bleeding headlines and crude already down nine percent. Sunday, Washington and Tehran said they were standing down and heading to Doha. Whether that holds is anyone's guess, but for one trading day, at least, the market gets to price the calmer outcome.",
                "category": "company",
                "datetime": 1782726305,
                "headline": "Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Side"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 1,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.9,
            "source_article_count": 59,
            "discarded_article_count": 49
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 25.3,
        "grade": "優秀",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 3,
          "vcpPoints": 2.7,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": true,
            "vcp_score": 2.7,
            "vcp_reason": "波幅收縮(13.8%→7.7%)；跌縮量(近10日3日)；站上MA50；收盤突破20日高位；Ready=Y；Confirm=Y",
            "vcp_metrics": {
              "up_days": 6,
              "vol_ref": 901620,
              "down_days": 3,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 692680,
              "avg_vol_20": 748230,
              "avg_vol_30": 901620,
              "range_pct_10": 0.07671396007816626,
              "range_pct_20": 0.09902474321793983,
              "range_pct_30": 0.13842455390581648,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": true,
              "vol_ratio_10_30": 0.7682615736119429,
              "dist_to_20d_high": -0.0058599539883957864,
              "down_shrink_days": 3,
              "breakout_level_20d": 691.13,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.5541932981800478
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.4782934272892407,
              "turnoverUsdM": 610.48204073836,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.8,
          "stopLevels": {
            "symbol": "US.REGN",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 660.7228,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 3,
              "macd_score": 3,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.7,
            "stop_loss_percent": 5,
            "take_profit_price": 754.5612,
            "target_multiplier": 2.2,
            "technical_strength": 2.35,
            "take_profit_percent": 8.5
          },
          "positionPoints": 1.6,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.714889751633911,
          "stopLossPercent": 4.9565868545784815,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 100,
    "atr": {
      "atr": 17.2286,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.48
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 161.13
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0475
    },
    "kdj": {
      "d": 52.27,
      "j": 80.09,
      "k": 61.55,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 56.54
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 8,
      "trend": "資金入貨",
      "value": 149964,
      "recentSlope": 248096.4,
      "previousSlope": 126170
    },
    "rsi": 63.74,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 10,
      "trend": "上升",
      "value": 637.8,
      "position": "SAR由上轉下+趨勢強",
      "distancePct": 8.25,
      "previousTrend": "下降"
    },
    "ma50": 638.9202,
    "macd": {
      "macd": 8.903574248684436,
      "trend": "強烈看漲",
      "signal": 7.767000082243719,
      "histogram": 1.1365741664407167
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 8,
      "value": 659.154,
      "position": "連續3日>VWAP",
      "consecutiveAbove": 3
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.16,
      "score": 6,
      "avgVolume": 755418,
      "currentVolume": 878164
    },
    "derived": {
      "ma20": 661.6,
      "ma50": 638.9202,
      "prevClose": 667.17,
      "avgVolume10": 732696,
      "avgVolume20": 755418,
      "changePercent": 4.2,
      "avgVolumeForScore": 755418
    },
    "ma_cross": {
      "ma20": 661.6,
      "ma50": 638.9202,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 658.4315,
      "prevMa50": 639.274,
      "spreadPct": 3.55,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 628.3643,
      "upper": 694.8357,
      "position": "上半部"
    },
    "rsi_short": 66.21,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.16
    }
  }
}

{
  "close": 695.18,
  "volume": 878164,
  "changePercent": 4.2
}